Life Sciences
Top stories summarized by our editors
8/16/2019

Facebook has made changes to its marketing application programming interface to appease organizations calling on the platform to reduce discriminatory practices of advertisers targeting individuals based on ZIP code, age and gender for credit, housing and employment. Advertisers must now select a particular ad category in Facebook's Ads Manager when running these ads, which will limit targeting capabilities.

More Summaries:
Facebook
8/16/2019

Updated labeling was approved by the FDA for two of Merck's pediatric asthma treatments, Asmanex HFA, or mometasone furoate, and Dulera, or mometasone furoate and formoterol fumarate. The labels will indicate that Asmanex HFA can now be used to treat patients ages 5 years and older, and Dulera can now be used twice daily in patients with asthma who are at least 5 years old.

Full Story:
eMPR
8/16/2019

Researchers have developed a compound called DJ009, one of a hundred they created, to block protein tyrosine phosphatase-sigma in human stem cells, which quashes stem cell regeneration. Data from the study showed the compound accelerated blood stem cell and white blood cell recovery after mice underwent radiation therapy, according to the journal Nature Communications.

8/16/2019

D&D Pharmatech of South Korea gained $137.1 million through a Series B funding round that it will use to advance development pipelines of three of its subsidiaries -- Neuraly, Precision Molecular and Theraly Fibrosis -- that are focused on therapies to treat inflammation. D&D uses in-licensed technology from Johns Hopkins University.

Full Story:
BioCentury
8/16/2019

Motif Ingredients announced it will now be known as Motif FoodWorks, and that it recently gained $27.5 million in additional funding to support the development of its pipeline for animal-free protein ingredients, such as milk and meat. The company plans to become a supplier of ingredients that will enhance the texture and flavor of plant-based beverages and foods.

Full Story:
Xconomy
8/16/2019

AbbVie spent more than $42.5 million on eight television ads for Humira in July, significantly more than other drug companies. The second top spender was Gilead Sciences' Truvada with one ad at a cost of $19.7 million, followed by Pfizer and Bristol-Myers Squibb's Eliquis with three ads at $15.7 million.

Full Story:
FiercePharma
8/16/2019

The FDA has unveiled a proposed rule that would require all cigarette packaging to include one of 13 new warning labels with graphic images and detailed descriptions of lesser-known smoking-related health risks, such as stunted fetal growth, cataracts and bladder cancer. The graphic warning labels "are a dramatic improvement over the current text-only warnings that have become stale and unnoticed," according to a joint statement from the American Academy of Pediatrics and other health organizations.

8/16/2019

Select ImmunoGenomics has been acquired by GeneCentric Therapeutics. Select offers data analysis, biomarker development and advanced immunogenomic services for immuno-oncology drug studies.

More Summaries:
GeneCentric Therapeutics
8/16/2019

Alphatec has appointed former NuVasive executives Eric Dasso and Timothy Day as the new executive vice president of adjunctive technologies and territory development manager for the northeast, respectively. The company also hired former Stryker Spine executive Wyatt Stanfield as area vice president of sales for the west.

Full Story:
Becker's Spine Review
More Summaries:
Alphatec, NuVasive
8/16/2019

Baxter Renal Care said during a second-quarter earnings call that its main drivers of growth for the quarter included hemostats and sealants, IV infusion systems, its peritoneal dialysis and continuous renal replacement therapies, and certain generic pharmaceuticals. However, the recall of its Revaclear hemodialyzers will result in a revenue loss of about $20 million this year.

More Summaries:
Baxter Renal Care